Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.

de Vos S, Wagner-Johnston ND, Coutre SE, Flinn IW, Schreeder MT, Fowler NH, Sharman JP, Boccia RV, Barrientos JC, Rai KR, Boyd TE, Furman RR, Kim Y, Godfrey WR, Leonard JP

Open source

DOI: 10.1182/bloodadvances.2016000976
Published: 2016 Dec 13
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2016000976,
  title = {Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.},
  author = {de Vos S and Wagner-Johnston ND and Coutre SE and Flinn IW and Schreeder MT and Fowler NH and Sharman JP and Boccia RV and Barrientos JC and Rai KR and Boyd TE and Furman RR and Kim Y and Godfrey WR and Leonard JP},
  year = {2016},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2016000976},
  url = {https://doi.org/10.1182/bloodadvances.2016000976}
}

RIS

TY  - JOUR
TI  - Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.
AU  - de Vos S
AU  - Wagner-Johnston ND
AU  - Coutre SE
AU  - Flinn IW
AU  - Schreeder MT
AU  - Fowler NH
AU  - Sharman JP
AU  - Boccia RV
AU  - Barrientos JC
AU  - Rai KR
AU  - Boyd TE
AU  - Furman RR
AU  - Kim Y
AU  - Godfrey WR
AU  - Leonard JP
PY  - 2016
JO  - Blood advances
DO  - 10.1182/bloodadvances.2016000976
UR  - https://doi.org/10.1182/bloodadvances.2016000976
ER  -

APA

S, D. V., ND, W., SE, C., IW, F., MT, S., NH, F., JP, S., RV, B., JC, B., KR, R., TE, B., RR, F., Y, K., WR, G., & JP, L. (2016). Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.. Blood advances. https://doi.org/10.1182/bloodadvances.2016000976

Source records

pubmed · retrieved 2026-09-25T06:46:56.402Z